CION Ameerpet
Men carry BRCA variants and pass them on exactly as women do — half their children, sons and daughters alike. They also have raised risks of their own, and both facts are routinely overlooked.
Because the single most common reason hereditary ovarian cancer risk goes unrecognised is that nobody asked about the father's side. BRCA1 and BRCA2 sit on ordinary chromosomes, not sex chromosomes, so they are inherited and transmitted identically by men and women. A father passes his variant to about half his children — sons and daughters alike.
The reason his side of the family can look unremarkable is not genetic but statistical. A male carrier's own cancer risks are real but lower and later than a female carrier's, so he may live a long life without any diagnosis. If he has few female relatives, or his sisters were unaffected, that branch shows nothing at all. The variant travels silently through a generation and surfaces in a granddaughter, whose doctors ask about her mother's side and find nothing.
So a woman worried about ovarian cancer has two reasons to care about male carriers. Her own risk may have come through her father. And if she carries a variant, her brothers and sons are equally likely to carry it — with implications both for their own health and for their children.
BRCA genes are on ordinary chromosomes. Men transmit them to half their children, sons and daughters equally.
Male carriers' own risks are lower and later, so a branch can look unremarkable while carrying the variant.
If you carry a variant, your male relatives are equally likely to — for their own health and their children's.
Testing a man can be the most efficient step a whole family takes. If your aunt carries a variant, your own risk depends on whether your father inherited it from the same parent she did — and testing him answers that directly. If he is negative, you and all your siblings need no testing at all, and that entire branch of the family closes. If he is positive, testing you becomes targeted and definitive. One test on a man who may never develop cancer himself can resolve the position for a dozen relatives. It is frequently never suggested. Source: NCCN Genetic/Familial High-Risk Assessment guidelines.
Lower than the corresponding female risks, and genuinely present. BRCA2 carries more of them than BRCA1.
| Cancer | Association | What it means in practice |
|---|---|---|
| Male breast cancer | Clearly increased, mainly with BRCA2. | Male breast cancer is uncommon overall; a single case in a family strongly suggests BRCA2. Breast awareness matters. |
| Prostate cancer | Increased, and more often aggressive with BRCA2. | Earlier and more active PSA surveillance is generally discussed with carriers. |
| Pancreatic cancer | Modestly increased, more clearly with BRCA2. | Surveillance is discussed in selected families, usually where there is also a family history of it. |
| Transmission to children | 50% for each child, regardless of sex. | Identical to a female carrier. This is often the most consequential implication. |
*Risk estimates vary between studies and by gene. BRCA2 carries the clearer associations for men. Specific figures are best discussed with a genetics service using your own gene and family history.
Less than for a woman in terms of his own management, and just as much in terms of his family.
This is the most concrete change to a male carrier's own care. BRCA carriers, particularly BRCA2, have an increased risk of prostate cancer and it is more often the aggressive kind rather than the indolent disease that many men die with rather than of.
PSA surveillance from a younger age is generally discussed, along with a lower threshold for further investigation. The specifics vary by guideline and by individual circumstances, and are worth agreeing with a urologist rather than assuming.
Male breast cancer is uncommon, which is precisely why it tends to present late — men do not expect it and neither, sometimes, do the clinicians they first see. A lump behind the nipple, a nipple change, skin dimpling or nipple discharge all warrant prompt assessment in a male carrier.
There is no screening programme for men, so awareness does the work here. It is worth knowing what to look for and having a low threshold for getting it checked rather than waiting to see whether it settles.
Frequently the most significant consequence, and the one that motivates most men to test. Each child has a fifty per cent chance of inheriting the variant, and for daughters that means substantially raised ovarian and breast cancer risk with genuinely effective interventions available.
A father who knows his status gives his daughters access to risk assessment they would otherwise never be offered — because their doctors would be asking about their mother's side. See cascade testing.
Pancreatic cancer risk is modestly increased, more clearly with BRCA2. Surveillance is not routine for all carriers, because pancreatic screening is difficult and not straightforwardly beneficial, but it is discussed in selected families — typically where there is also a family history of pancreatic cancer.
This is an area where practice varies and is evolving, so it is worth asking rather than assuming either that it is offered or that it is not.
BRCA status affects treatment as well as risk. Prostate cancer arising in a BRCA carrier has impaired DNA repair, which makes it responsive to certain systemic treatments including PARP-inhibitor-class drugs — the same logic that applies in ovarian cancer.
This is why testing is increasingly offered to men diagnosed with advanced or aggressive prostate cancer regardless of family history: the result guides the patient's own treatment, not only his relatives' risk assessment.
There is no equivalent of risk-reducing surgery for male carriers — nothing analogous to salpingo-oophorectomy is offered, and the substantially lower absolute risks mean nothing of that kind would be justified.
Male carriers are not routinely offered breast screening either, because male breast cancer, while raised in relative terms, remains uncommon enough that a screening programme would do more harm than good. Awareness and prompt assessment of symptoms is the approach.
Any one of these is a reasonable reason. Several apply to men who feel the question has nothing to do with them.
A parent, sibling or child with an identified variant. Testing is targeted, quick and gives a clear answer.
It came from somewhere. Establishing which side it runs down clarifies the position for the whole family.
Ovarian cancer in your mother, sister or daughter is a recognised indication for genetic assessment in the family.
Uncommon and strongly associated with BRCA2. A single case warrants a genetics discussion.
Testing is increasingly offered at diagnosis, because the result guides treatment as well as informing relatives.
Especially in more than one relative. Your side of the family counts fully in a risk assessment.
A man who tests negative for a known family variant cannot pass it on, and his children need no testing. That is a genuinely definitive result for an entire branch.
If a man tests negative for the family's variant, his children need no testing at all. One test can close an entire branch of a family tree.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Genetic counselling and BRCA testing are delivered in-house at CION, for men and women alike.
Men are consistently under-tested in hereditary cancer, and the reasons are cultural rather than clinical. BRCA is framed as a women's issue, family histories are taken down the maternal line, and men who would readily do something for their daughters are simply never asked.
Your first consultation at CION is free and runs to about 45 minutes, and genetic counselling and BRCA testing are delivered in-house for men as much as for women. If a variant has been identified anywhere in your family, testing you for that specific change is targeted, quick and gives an unambiguous answer — and it may close an entire branch of the family tree.
Where a variant is confirmed, the plan covers your own surveillance — prostate in particular — and what it means for your children. Where cancer does develop, medical oncology including PARP-inhibitor-class treatment is delivered in-house across 35+ centres in Telangana and Andhra Pradesh. Any surgery is coordinated with specialist partner centres and may be billed there.
BRCA is framed as a women's issue and family histories are taken maternally. Both are why men get missed.
A negative result in a father means his children need no testing at all. That is a large return on one blood sample.
Free and unhurried, and genetic counselling is in-house for men as much as for women.
Where a variant is confirmed, earlier and more active PSA surveillance is part of the plan.
Women who carry a variant often find male relatives the hardest to persuade — not out of hostility, but because the framing has never included them. A brother who has heard BRCA described repeatedly as a breast and ovarian cancer gene may reasonably conclude it does not concern him.
Two framings work better than the risk figures. The first is his children: if he carries it, each of his sons and daughters has a fifty per cent chance, and his daughters in particular would gain access to risk assessment and effective interventions they would otherwise never be offered. Many men who are indifferent about their own risk are not indifferent about that.
The second is that a negative result closes the question for his whole branch — his children need no testing, and nobody in that line has to think about it again. That is a concrete, finite outcome rather than an open-ended commitment, and it tends to land better than a discussion of relative risks. Ask your genetics service for a family letter; it does the explaining for you.
BRCA is described as a breast and ovarian gene, so male relatives reasonably conclude it is not about them.
Fifty per cent for each. Men indifferent to their own risk are frequently not indifferent to their daughters'.
Finite and concrete: his children need no testing and that line stops thinking about it.
Ask your genetics service for one. It states the variant precisely and does the explaining for you.
Yes, exactly as women do. BRCA1 and BRCA2 sit on ordinary chromosomes rather than sex chromosomes, so inheritance and transmission are identical regardless of sex. A male carrier passes the variant to approximately half his children, sons and daughters alike. This is why a family history taken only down the maternal line is incomplete, and why hereditary ovarian cancer risk is so often unrecognised — a variant can travel silently through a male generation and surface in a granddaughter whose doctors ask only about her mother's side.
Increased risks of male breast cancer, prostate cancer and pancreatic cancer, most clearly associated with BRCA2 rather than BRCA1. Male breast cancer is uncommon overall, so a single case in a family is a strong signal of BRCA2. Prostate cancer risk is increased and the disease is more often aggressive in carriers, which is why earlier and more active PSA surveillance is generally discussed. Pancreatic risk is modestly raised. In absolute terms these are all considerably lower than the corresponding risks a female carrier faces, which is precisely why male carriers can go unrecognised.
Because it can answer the question for you and all your siblings at once. If a variant has been identified elsewhere in the family — an aunt, for example — your own risk depends on whether your father inherited it. Testing him directly resolves that: if he is negative, he cannot have passed it on, so you and your siblings need no testing and that entire branch closes. If he is positive, testing you becomes a targeted, definitive question. One test on a man who may never develop cancer himself can settle the position for a dozen relatives, and it is frequently never suggested.
No. There is no male equivalent of risk-reducing salpingo-oophorectomy, and the substantially lower absolute risks mean nothing of that kind would be justified. Male carriers are not routinely offered breast screening either, because male breast cancer — while raised in relative terms — remains uncommon enough that a screening programme would do more harm than good. What is offered is earlier and more active prostate surveillance, awareness of breast symptoms with a low threshold for assessment, and in selected families a discussion about pancreatic surveillance.
Increasingly yes, particularly where the disease is advanced or aggressive, and regardless of family history. The reason is that the result guides treatment as well as informing relatives. Prostate cancer arising in a BRCA carrier has impaired DNA repair, which makes it responsive to certain systemic treatments including PARP-inhibitor-class drugs — the same biological logic that applies in ovarian cancer. So the test is not only about risk assessment for the family; it can change what treatment options are available to the man himself.
Two framings work better than risk figures. Lead with his children: each has a fifty per cent chance of carrying the variant, and his daughters in particular would gain access to risk assessment and genuinely effective interventions they would otherwise never be offered, because their doctors would be asking about their mother's side. Many men who are indifferent about their own risk are not indifferent about that. The second is that a negative result closes the question permanently for his whole branch — concrete and finite rather than an open-ended commitment. Ask your genetics service for a family letter.
Yes. Genetic counselling and BRCA and HRD testing are delivered in-house at CION for men as much as for women, and the first consultation is free and runs to about 45 minutes. If a variant has already been identified in your family, testing you for that specific change is targeted, quick and gives an unambiguous answer. Where a variant is confirmed, the plan covers your own surveillance — prostate in particular — and the implications for your children. Medical oncology is delivered in-house across more than 35 centres; surgery is coordinated with specialist partner centres and may be billed there.